Bellevue Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.9K | Sell |
5,514
-189,538
| -97% | -$959K | ﹤0.01% | 141 |
|
|
2025
Q1 | $1.03M | Sell |
195,052
-182,754
| -48% | -$967K | 0.02% | 107 |
|
|
2024
Q4 | $2.55M | Sell |
377,806
-15,075
| -4% | -$102K | 0.05% | 105 |
|
|
2024
Q3 | $2.59M | Sell |
392,881
-32,929
| -8% | -$217K | 0.04% | 104 |
|
|
2024
Q2 | $3.19M | Buy |
425,810
+561
| +0.1% | +$4.21K | 0.05% | 104 |
|
|
2024
Q1 | $4.24M | Buy |
425,249
+250,692
| +144% | +$2.5M | 0.06% | 99 |
|
|
2023
Q4 | $1.72M | Buy |
174,557
+472
| +0.3% | +$4.65K | 0.03% | 109 |
|
|
2023
Q3 | $1.33M | Buy |
+174,085
| New | +$1.33M | 0.02% | 120 |
|
|
2021
Q3 | – | Sell |
-20,000
| Closed | -$730K | – | 221 |
|
|
2021
Q2 | $730K | Buy |
+20,000
| New | +$730K | 0.01% | 152 |
|